These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
477 related articles for article (PubMed ID: 19520215)
1. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Bryant BJ; Im K; Broome DR Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215 [TBL] [Abstract][Full Text] [Related]
2. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633 [TBL] [Abstract][Full Text] [Related]
3. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927 [TBL] [Abstract][Full Text] [Related]
4. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973 [TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233 [TBL] [Abstract][Full Text] [Related]
6. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495 [TBL] [Abstract][Full Text] [Related]
7. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631 [TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan. Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824 [TBL] [Abstract][Full Text] [Related]
16. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457 [TBL] [Abstract][Full Text] [Related]
17. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)]. Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607 [TBL] [Abstract][Full Text] [Related]
18. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose. Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901 [TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Hope TA; Herfkens RJ; Denianke KS; LeBoit PE; Hung YY; Weil E Invest Radiol; 2009 Mar; 44(3):135-9. PubMed ID: 19151610 [TBL] [Abstract][Full Text] [Related]
20. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience. Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]